Genome instability in multiple myeloma DOI

Carl Jannes Neuse,

Oliver Lomas, Christoph Schliemann

et al.

Leukemia, Journal Year: 2020, Volume and Issue: 34(11), P. 2887 - 2897

Published: July 10, 2020

Language: Английский

A view on drug resistance in cancer DOI Open Access
Neil Vasan, José Baselga, David M. Hyman

et al.

Nature, Journal Year: 2019, Volume and Issue: 575(7782), P. 299 - 309

Published: Nov. 13, 2019

Language: Английский

Citations

2065
Intratumoral heterogeneity in cancer progression and response to immunotherapy DOI
Ilio Vitale, Efrat Shema, Sherene Loi

et al.

Nature Medicine, Journal Year: 2021, Volume and Issue: 27(2), P. 212 - 224

Published: Feb. 1, 2021

Language: Английский

Citations

571
Context is everything: aneuploidy in cancer DOI
Uri Ben‐David, Angelika Amon

Nature Reviews Genetics, Journal Year: 2019, Volume and Issue: 21(1), P. 44 - 62

Published: Sept. 23, 2019

Language: Английский

Citations

570
Targeting non-coding RNAs to overcome cancer therapy resistance DOI Creative Commons
Baoqing Chen, Mihnea P. Dragomir, Yang Chen

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2022, Volume and Issue: 7(1)

Published: April 13, 2022

Abstract It is now well known that non-coding RNAs (ncRNAs), rather than protein-coding transcripts, are the preponderant RNA transcripts. NcRNAs, particularly microRNAs (miRNAs), long (lncRNAs), and circular (circRNAs), widely appreciated as pervasive regulators of multiple cancer hallmarks such proliferation, apoptosis, invasion, metastasis, genomic instability. Despite recent discoveries in therapy, resistance to chemotherapy, radiotherapy, targeted immunotherapy continue be a major setback. Recent studies have shown ncRNAs also play role different therapies by rewiring essential signaling pathways. In this review, we present intricate mechanisms through which dysregulated control four types therapies. We will focus on current clinical implications biomarkers predict treatment response (intrinsic resistance) detect therapy after start (acquired resistance). Furthermore, potential targeting ncRNA overcome resistance, discuss challenges ncRNA-targeted therapy—especially development delivery systems.

Language: Английский

Citations

252
Rational combinations of targeted cancer therapies: background, advances and challenges DOI
Haojie Jin, Liqin Wang, René Bernards

et al.

Nature Reviews Drug Discovery, Journal Year: 2022, Volume and Issue: 22(3), P. 213 - 234

Published: Dec. 12, 2022

Language: Английский

Citations

246
cGAS–STING drives the IL-6-dependent survival of chromosomally instable cancers DOI
Christy Hong, Michaël Schubert, Andréa E. Tijhuis

et al.

Nature, Journal Year: 2022, Volume and Issue: 607(7918), P. 366 - 373

Published: June 15, 2022

Language: Английский

Citations

236
Taxanes in cancer treatment: Activity, chemoresistance and its overcoming DOI
Luciana Mosca, Andrea Ilari, Francesco Fazi

et al.

Drug Resistance Updates, Journal Year: 2021, Volume and Issue: 54, P. 100742 - 100742

Published: Jan. 1, 2021

Language: Английский

Citations

228
Genomic evolution of cancer models: perils and opportunities DOI
Uri Ben‐David,

Rameen Beroukhim,

Todd R. Golub

et al.

Nature reviews. Cancer, Journal Year: 2018, Volume and Issue: 19(2), P. 97 - 109

Published: Dec. 21, 2018

Language: Английский

Citations

193
Ongoing chromosomal instability and karyotype evolution in human colorectal cancer organoids DOI

Ana C.F. Bolhaqueiro,

Bas Ponsioen, Björn Bakker

et al.

Nature Genetics, Journal Year: 2019, Volume and Issue: 51(5), P. 824 - 834

Published: April 29, 2019

Language: Английский

Citations

193
In Vivo Lineage Tracing of Polyploid Hepatocytes Reveals Extensive Proliferation during Liver Regeneration DOI Creative Commons
Tomonori Matsumoto, Leslie Wakefield, Branden Tarlow

et al.

Cell stem cell, Journal Year: 2019, Volume and Issue: 26(1), P. 34 - 47.e3

Published: Dec. 19, 2019

Language: Английский

Citations

163